Oncology · Immune TherapyTrial Updateclinicalmid-term

ASP1570 Study in Advanced Solid Tumors with Pembrolizumab and Standard Therapies

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/4/2026, 6:02:49 AM

Assessment confidence: 87% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of ASP1570 in combination with pembrolizumab and standard therapies could significantly impact treatment protocols for advanced solid tumors. Positive outcomes may enhance competitive positioning for companies in the immune-oncology space, particularly for those targeting resistant cancers. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 21 ranked evidence items (19 high-relevance).

Strategic Assessment

The outcomes of this trial may influence treatment protocols and competitive positioning for companies involved in immune-oncology therapies. The strongest clinical anchor is A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (ClinicalTrials.gov), entity match (pembrolizumab). In Oncology · Immune Therapy, 1 regulatory and 6 competitive items passed relevance filtering for ASP1570.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck); patient population match (advanced). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Patient population match (advanced). The trial results will be critical for regulatory approvals and may lead to new treatment guidelines, affecting compliance and market access for involved therapies.

Key Risks

Elevated medium regulatory exposure for ASP1570 could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise) could weigh on ASP1570 through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

If ASP1570 proves effective, it could capture market share from existing therapies, influencing revenue streams for companies involved in immune-oncology treatments.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for ASP1570 may improve if A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies (ClinicalTrials.gov) delivers favorable follow-through.
Upside for ASP1570 may improve if An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy data, as well as any announcements regarding dosing adjustments or combination therapy outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Patient population match (advanced)
FDA document
View source

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govhigh relevance
Entity match (pembrolizumab)
FDA document
View source
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
ClinicalTrials.govhigh relevance
Entity match (pembrolizumab)
FDA document
View source
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
ClinicalTrials.govhigh relevance
Entity match (pembrolizumab)
FDA document
View source
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas
Humanexa Signalshigh relevance
Patient population match (advanced)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise
Humanexa Signalsmedium relevance
Moderate corpus alignment

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Entity match (pembrolizumab)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (advanced)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedhigh relevance
Patient population match (advanced)
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ASP1570
pembrolizumab
immune-oncology therapies

Commercial impact

medium

If ASP1570 proves effective, it could capture market share from existing therapies, influencing revenue streams for companies involved in immune-oncology treatments.

Regulatory impact

medium

The trial results will be critical for regulatory approvals and may lead to new treatment guidelines, affecting compliance and market access for involved therapies.

What to watch

Monitor trial results for safety and efficacy data, as well as any announcements regarding dosing adjustments or combination therapy outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.